Clinical study on sequential treatment of newly diagnosed de novo acute myeloid leukemia patients with IA and low-dose HA combined with G-CSF regimens as remission induction therapy
10.3760/cma.j.issn.1009-9921.2012.08.010
- VernacularTitle:IA联合小剂量HA+G-CSF方案序贯治疗原发初治急性髓系白血病的临床研究
- Author:
Zhengjin ZHENG
;
Shaoyuan WANG
;
Langhui ZHANG
;
Qingxiao SONG
;
Jiangrui GUO
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
Drug therapy,combination
- From:
Journal of Leukemia & Lymphoma
2012;21(8):481-483
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of sequential treatment of newly diagnosed de novo acute myeloid leukemia (AML) patients with IA and low-dose HA combined with G-CSF regimens as remission induction therapy.Methods Fifty-seven patients with AML were enrolled,which marrow biopsy was hypocellular or active proliferation on the third day from the end of the first course with IA regimen.32 cases of them received the second course with low-dose HA combined with G-CSF regimen,compared with other 25 cases received the second course with another IA regimen.Clinical manifestations,blood count,blood biochemical parameters and bone marrow smears were measured during the courses.Results In study group,21 of 32 cases reached CR,4 PR,and 11 of 20 cases reached CR,2 PR in control group.Overall remission rate (ORR) was higher in study group than that in control group (78.1％ vs 52.0 ％,P =0.038).Both median duration of agranulocytosis and median time for PLT to reach 50×109/L from the lowest were shorter in study group than those in control group (9.5 d vs 28.0 d,U=32.5,P＜ 0.001; 11 d vs 19 d,U=193.0,P=0.001).Component transfusion,not only RBC but PLT,decreased in study group,compared with control group (8 U vs 16 U,U =206.5,P =0.002; 20 U vs 60 U,U =149,P ＜ 0.001).Median durable time of antibiotic intravenous injection was shorter in study group than that in control group (14 d vs 21 d,U=249.5,P=0.015).Visceral hemorrhage rate reduced in study group,compared with control group (x2 =3.90,P =0.048).Conclusion IA and low-dose HA combined with G-CSF regimens sequential treatment as remission induction therapy for newly diagnosed de novo AML patients is effective and well tolerated.
